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S328 Poster Session IIunrelated donors [9/10HR5 9 (4-20), p\0.001; 10/10HR5 4 (1.2-
10), p 5 0.03], female donors [HR 5 3 (1.2-7); p 5 0.01] and ABO
minor incompatibility [HR5 2.5 (1.2-5), p5 0.01].We showed that
allo-HSCTfrom9/10HLAmismatchedunrelated donors have a sig-
nificantly worse OS than those from matched unrelated donors and
siblings; this was mainly due to an increased TRM in this group. Pa-
tients in first CR or CP could benefit themore frommatched or 9/10
unrelated allo-HSCT while the use of transplants from 9/10 HLA
unrelated donors in patients not in CR1 should be limited to clinical
trials.
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Introduction: A small minority of patients (pts) with AcuteMyeloid
Leukemia (AML) achieve complete remission (CR3) after a second
relapse. The role of allogeneic HCT (allo-HCT) for such patients
is unclear. Here we present the outcomes of CR3 AML patients
treated at the M D Anderson Cancer Center.
Methods: We conducted a retrospective analysis of prospectively
collected data on all AML pts (n 5 33) who received their allo-
HCT in $ CR3 between 11/2/1990- 7/1/2009.
Results:Median age was 40 years (range, 19-67) and 46% were fe-
male. CR3 pts comprised 2.7% of all pts with AML treated at the
same time period in our institution (n 5 1227). 3/33 had secondary
AML (2 with prior myelodysplastic syndrome and one with previ-
ous myeloproliferative disorder). Cytogenetics risk categories were
low in 24%, intermediate in 30%, high in 21% and unknown in
25%. Pts had a median of 4 chemotherapy lines prior to transplant.
Donor was matched unrelated in 48%, matched related in 24%,
mismatched related in 15% and mismatched unrelated 9%. Graft
source was peripheral blood (52%), marrow (39%) or umbilical
cord blood (9%). Ten pts had prior allo-HCT. Conditioning reg-
imen was of reduced intensity in 60% and myeloablative in 40% of
pts. and 84% of pts received Tacrolimus/Methotrexate +/- Pentos-
tatin for graft- versus-host disease (GVHD) prophylaxis. 97% of
the pts engrafted. Cumulative incidence rate of grade II-IV acute
GVHD was 26% and of chronic GVHD was 27%. Overall survival
was 19% (95 % CI: 7-34%) and progression-free survival (PFS)
was 12% (95% CI: 3-26%)[Figure below]. Relapse rate was 29%,
and cumulative incidence of non relapse mortality (NRM) was
46%. Less NRM was seen among pts who had allo-HCT after
year 2002, year in which molecular class I HLA typing was incor-
porated (32% vs. 64%; p 5 0.9); improved PFS was also observed
after 2002 (22% vs. 0% before 2002, p 5 0.5). Prior allo-HCT was
not a risk factor for adverse outcomes with PFS of 20% with prior
HCT vs. 7% for pts without prior allo-HCT (p 5 0.7) and NRM
rates were comparable (20% vs. 58%; p 5 0.3). Seven pts are alive,
with a median follow-up of 11.3 months. Causes of death (n 5 26)
were relapse (n 5 7), infections (n 5 8), GVHD (n 5 5), other (n 5
3), and unknown (n 5 3).
Conclusions: Pts in CR3may benefit from allo-HCT, but should be
considered for investigational approaches given high non-relapse
and relapse mortality.
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BROAD EXPRESSION OF A MINOR HISTOCOMPATIBILITY ANTIGEN RE-
SULTS IN IMPAIRED ANTITUMOR IMMUNITY THAT CANNOT BE OVER-
COME WITH DENDRITIC CELL VACCINATION
Shand, J.C.1, Capitini, C.M.2, Qin, H.2, Fry, T.J.2 1Johns Hopkins Uni-
versity-National Cancer Institute Combined Fellowship, Baltimore and
Bethesda, MD; 2National Cancer Institute, Bethesda, MD
Although allogeneic transplant remains a potent immunotherapy
for high-risk hematopoetic malignancies, relapse is the main cause
of treatment failure. We, and others, have shown that alloreactivity
associated with minor histocompatibility antigen (miHA) mismatchreduces quantitative responses to vaccines targeting tumor-specific
antigens. The effect of miHA mismatch on the antitumor response
when the tumor also expresses the miHA has not been well-studied,
and could provide important insight into the biology of the graft-ver-
sus-tumor effect. We therefore utilized a murine allotransplant sys-
tem in which donors and recipients weremismatched at the clinically
relevant male miHA HY, followed by DLI with HY-specific T cells
and challenge with an HY-expressing tumor. Professional HY anti-
gen presentation was provided at the time of DLI using an activated
male dendritic cell (DC) vaccine. Recipients were monitored for
clinical GVHD and antitumor responses measured by tumor-free
and overall survival. Further analysis of HY specific T-cells in sec-
ondary lymphoid organs was performed by flow cytometry using
congenic markers.WhenHY is expressed only on the tumor, follow-
ing syngeneic transplant of female (HY-naive) T-cell depleted mar-
row into female recipients, there is 100% tumor-free survival
following HY-specific DLI and male vaccination. However, when
HY is expressed in all nonhematopoetic tissues, following transplan-
tation of female marrow into male recipients, there is approximately
20% tumor-free survival regardless of whether an activatedmale DC
vaccine is given. Interestingly, expression of HY in both the non-
hematopoetic and hematopoetic (when male marrow is transplanted
into female recipients) compartments produces a robust expansion of
HY-specific T-cells, suggesting that the impaired antitumor immu-
nity is due to dysfunction, rather than clonal deletion. Indeed, nearly
100% of HY-specific T-cells from secondary lymphoid organs ex-
press high levels of PD-1 in the allogeneic transplant setting, com-
pared to low levels in syngeneic recipients and no expression in
lymphocytes reconstituted independently of the DLI. Studies are
underway to functionally characterize these exhausted alloreactive
T cells and and identify targets for therapeutic blockade to restore
the effectiveness of antitumor vaccination in the allotransplant set-
ting while minimizing GVHD.335
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Background: It is estimated that over 2,000,000 people suffer from
hepatitis C virus (HCV) infection in Japan. Therefore, HCV infec-
tion is one of major liver diseases. In hematopoietic stem cell trans-
plantation (HSCT), HCV infections of recipients might induce
a transient liver dysfunction, and an increasing risk of veno-occlusive
disease (VOD), although these are controversial. In addition, the ge-
notypes of HCV in Japan are considered different from those in
Western countries. Therefore, we have assessed the impact of
HCV sero-positivity of recipients on clinical outcomes in Japan.
Patients: The population was based on TRUMP data confirmed in
2010. The eligible population included the all recipients who re-
ceived an initial allogeneic HSCT since 2006 and whose data about
age, gender, HCV sero-positivity of recipients and status of survival
at last observation were available.
Results: We identified 136 and 7720 recipients with and without
HCV, respectively. Although more recipients with HCV tended
to be male (p 5 0.054) and to receive female to male HSCT
(p 5 0.081), there were no differences in other background. The
recovery of more than 5x10^10/L platelet was significantly later
in recipients with HCV (38 vs 47 days, p 5 0.013), while there
was no significant difference in neutrophil engraftment. There
were no differences between groups without and with HCV in
Poster Session II S329the incidences of grade2-4 aGVHD (35.9% vs 31.6%, p 5 0.18)
and cGVHD (29.3% vs 30.5%, p 5 0.67). However, the liver in-
volvement of aGVHD was higher in recipients with HCV
(13.9% vs 23.9%, p 5 0.031), while there was no differences in
liver involvement of cGVHD (37.3% vs 45%, p 5 0.33) and
VOD (10.7% vs 17.3%, p 5 0.17). Furthermore, the recipients
with HCV had significantly higher non-relapse mortality (NRM;
25.9% vs 38.0% at 2 year, p\0.01) and poor overall survival
(OS; 51.4% vs 41.1% at 2 year, p\0.01). Multivariate analysis re-
vealed that HCV sero-positivity remained significant as a risk fac-
tor for NRM (HR 1.60, p\0.01) and OS (HR 1.34, p 5 0.016)
after adjusting with gender, age, disease, and donor source. Propor-
tions of patients who died due to hepatic failure (4.9% vs 14.3%)
and bacterial infection (9.4% vs 18.2%) were significantly higher
in recipients with HCV than in those without HCV.
Conclusion: HCV sero-positivity was identified as a risk factor for
poor survival in HSCT. In addition, we should carefully manage
not only liver dysfunction but also bacterial infection in HCV posi-
tive patients.336
DEPLETION OF HOST DENDRITIC CELLS DURING THE EFFECTOR PHASE
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After allogeneic stem cell transplantation remaining recipient
dendritic cells (DCs) in secondary lymphoid organs are essential
to initiate acute graft-versus-host disease (aGVHD). Yet, to which
extend mucosal DCs in peripheral tissues contribute to augment,
maintain or even down-modulate aGVHD remains elusive. There-
fore, we investigated the function of host DCs during the effector
phase of intestinal aGVHD. Until day 8 after transplantation
(H-2q FVB/N into H-2b C57BL/6, 9Gy) we detected predomi-
nantly persisting host DCs but only few donor DCs by immunoflu-
orescence microscopy. Histopathological analysis revealed high
numbers of host DC - donor T cell contacts in the intestinal mu-
cosa during the aGVHD effector phase. Time kinetics experiments
established that these dominating population of CD11c+CD11b+
intestinal DCs arose from radiation-resistant host-type monocytes
that were attracted to areas of inflammation and differentiated
into DCs. At sites of T cell contact DCs engaged costimulatory
molecules such as CD80. To address the role of this interaction
we induced aGVHD in transgenic C57Bl/6-DOG mice that ex-
press the diphtheria toxin (DTx) receptor in DCs under the control
of the CD11c promoter and subsequently applied DTx intraperito-
neally to eliminate host type DCs. Immunofluorescence micros-
copy and FACS analysis proved efficient host DC depletion in
the intestinal tract (.90%). DC depleted DOG recipients pre-
sented considerably higher GVHD scores and reduced survival
than aGVHD controls that did not receive DTx (n 5 25/group).
Additional controls were used in order to rule out possible cyto-
toxic effects of the DTx: WT mice, syngeneic controls and bone
marrow controls sensitive to the toxin, were not affected by the ad-
ministration of DTx. Subsequently we excluded a possible reduc-
tion of FoxP3+ regulatory T cells in the intestinal tract from
DTx and non-DTx treated mice. Inflammatory cytokines such as
IFN-g and TNF did not differ in the serum of DTx and non-
DTx treated mice on day 6 after allo-HCT, ruling out a possible
cytokine storm effect due to the DC killing. However, elevated
levels of the inflammatory cytokine CCL2 in DTx treated DOG
mice indicate that DC depletion enhances signals to recruit precur-
sors in order to refill the mucosal DC-compartment. Our study
provides evidence for a likely underappreciated function of DCs
during later stages of aGVHD and provides evidence for a protec-
tive role of remaining host DCs from monocytic origin during
aGVHD.337
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Introduction: BK-virus induced hemorrhagic cystitis (HC) fre-
quently affects patients undergoing allogeneic hematopoietic stem
cell transplant (allo-HSCT) and results in significant morbidity
and mortality. There are no existing guidelines to dictate clinical
practice.We present our institutional data and recommend a clinical
practice guideline that could potentially improve the outcomes of
patients with BK-virus infections.
Methods: Our retrospective analysis included 75 consecutive pa-
tients who underwent allo-HSCT from 2001-2011. Data was col-
lected on patients with PCR proven BK-viuria under existing IRB
approved protocols.
Results: 12% of all patients developed PCR proven HC. The me-
dian age of patients at transplant was 37-yrs. 66% had AML or
ALL and the median number of prior therapies was 3. 33% had
a MUD transplant while 66% received RIC conditioning and 33%
received ATG. The mean CD34+ cell dose was 4.8x106/kg and the
CD3+ cell dose was 8.6x1011/kg. The median time of onset of HC
was 44-days and lasted for an average of 53-days. 33% patients
were neutropenic at the onset of HC and the mean absolute neutro-
phil count was 4300/ul. Most common symptoms were dysuria in
66%, bladder spasms in 44% and urinary retention in 22%. All pa-
tients had receivedGVHDprophylaxis withmethotrexate and tacro-
limus and 77% were on concurrent steroids and mycophenolate.
88% of patients had concurrent acute GVHD at the time of HC.
88% had CMV and 11% had EBV viremia at the time of HC.
44% developed BK-viremia while 55% had BK-virus induced ne-
phropathy defined as an increase of serum creatinine.1.5. Manage-
ment approach was tiered into prophylaxis, symptomatic relief and
anti-viral therapy. All patients received ciprofloxacin and 88% re-
ceived IVIg.No single therapy component including reduced immu-
nosuppression, cidofovir and leflunomide was independently
identified as a more efficacious option (p.0.05), but of the patients
who received cidofovir, 75% had resolution of symptoms and were
able to clear the BK-viuria.
Conclusion:Our analysis suggests that BK-virus induced HC is the
result of multifaceted host and donor interactions and the concurrent
use of immune altering therapies. We have also developed a multi-
tiered approach that includes prophylactic intervention for patients
undergoing T-cell depleting regimens; symptomatic management;
and antiviral therapy in select subsets of patients to uniformly man-
age our patients in an effort to improve clinical outcomes.338
IN-VIVO MODEL OF HUMAN ALLOGENEIC STEM CELL REJECTION IN NSG
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T cell alloreactivity against human CD34+ cells was tested for the
first time in-vivo in a NOD/SCID g-null (NSG) mouse model. Hu-
man allogeneic blood CD3+ T cells were co-transplanted with allo-
geneic cord blood CD34+ cells (2 x 105/mouse) in sublethally
irradiated mice at high (50:1, 10:1, 5:1) or low (2:1, 1:1, or 0.5:1)
CD3:CD34 cell ratio. Control mice received CD34+ cells alone.
At 6 weeks post transplant, marrow and spleen cells were harvested
and analyzed by flow cytometry. Independently of high or low
CD3:CD34 cell ratio of the graft, all the mice showed a reduced
overall number of huCD45+ cells in the marrow (p 5 0.0001) com-
pared to control. Stem cell graft failure was documented by detecting
only the engraftment of human T cells and no myeloid or B cells in
the marrow and spleen of mice at every T cell:CD34 ratio tested.
HuCD45+ T cells included CD4+ and CD8+ cells at normal ratio
and a low number of CD56+ cells. Failure to engraftment of
CD34+ cells was also confirmed by FISH analysis in animals
